Clinical Trial Detail

NCT ID NCT03223155
Title Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Chicago
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.